Investor Relations

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology.

Latest News

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

View Press Release

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

View Press Release

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

View Press Release
Company Presentation

Latest Presentation

Company Presentation

June 2024 Fact Sheet

Fact Sheet

June 2024 Fact Sheet

Upcoming Event

Special General Meeting of Shareholders

Company Overview

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology. Its liquid-nitrogen based systems use ultra cold temperatures to destroy tumors by freezing them. Supported by clinical experience across multiple areas of cancer care, IceCure is opening the door for quick, convenient office-based and CT room procedures. Cryoablation - It's your choice.

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Stock Snapshot

IR Contacts

Headquarters

IceCure Medical Ltd.
7 Ha’Eshel Street
PO Box 3163
Caesarea 3079504
Israel
T: +972-4-623-0333
F: +972-4-623-0222
investors@icecure-medical.com

Investor Relations

EVC Group
Michael Polyviou
Todd Kehrli
T: +1-732-933-2755
investors@icecure-medical.com
https://www.evcgroup.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com